
    
      Patients are randomized to receive azithromycin alone, rifabutin alone, or the two drugs in
      combination for MAC prophylaxis. Patients in each treatment group further receive one of two
      doses of concomitant fluconazole for deep fungal prophylaxis, unless specifically excluded
      for fluconazole randomization. Patients are followed for 1 to 2 years.
    
  